Testing BRCA1 Variants Across Cell Types Clarifies Breast Cancer Risk Differences

Researchers at the Francis Crick Institute have systematically tested thousands of possible BRCA1 mutations in mammary gland cells, demonstrating that the functional consequences of genetic variants can vary significantly depending on the specific cellular context in which they are expressed. The experimental study, published in Nature Genetics, provides critical evidence to help clarify which genetic alterations confer a high risk of developing breast cancer and which carry intermediate effects. Mutations occurring within the BRCA1 gene, which normally functions to help repair damaged DNA, are widely recognized to increase the risk of breast and ovarian cancer. However, despite BRCA1 being among the most well-known and frequently tested cancer risk genes in medicine, many identified alterations have historically lacked definitive evidence regarding their true clinical significance.

To resolve these uncertainties and determine how individual sequence alterations disrupt cellular biology, Greg Findlay, who leads the Genome Function Laboratory at the Francis Crick Institute, developed an experimental approach termed saturation genome editing. Under this technique, genetic variants across a target gene are introduced one-by-one into cultured cells in a dish, allowing investigators to systematically track how each individual alteration modifies the gene’s functional activity. In the newly reported project, Findlay and Phoebe Dace, a former PhD student in the laboratory, applied this saturation genome editing platform to comprehensively test BRCA1 variants across distinct cellular environments.

The research team initiated their functional screening by editing more than 4,000 BRCA1 variants into a widely used laboratory model known as HAP1 cells, monitoring how each introduced change influenced cell growth. Through this high-throughput screen, Dace identified 538 specific variants that directly impacted gene function. These detrimental effects operated through two primary mechanisms: disrupting BRCA1’s essential interactions with other key partner proteins required for repairing damaged DNA, and impairing how the gene is expressed to manufacture its final protein product.

Because the measurable effects of genetic variants frequently depend on the biological context of the surrounding tissue, the scientists next investigated whether the patterns detected in standard laboratory cells held true in cells directly relevant to breast cancer. To test this question, the Crick team introduced the variants into human mammary epithelial cells. Upon analyzing the comparative results, the researchers observed that a notable subset of variants that had demonstrated severe, damaging effects in HAP1 cells produced much less of an effect when expressed in the human mammary cells.

This divergence proved highly informative for interpreting variant-associated disease risk, revealing that human mammary cells possess the ability to buffer certain functional impairments of the BRCA1 gene. Mutations that selectively impaired HAP1 cells while showing minimal consequences in mammary cells were found to be associated with an intermediate risk of developing breast cancer, rather than a uniformly high risk. The authors emphasized that identifying these intermediate-risk mutations has historically been challenging because their functional consequences are not as striking as alterations that cause severe impairment across multiple cell lineages.

Conversely, the experimental findings demonstrated that BRCA1 variants that produced harmful consequences across both cell types are associated with a higher risk of breast cancer. The researchers determined that this heightened cancer risk occurs because such dual-impairing mutations impose a substantially more severe impact on the fundamental ability of BRCA1 to repair cellular DNA damage. By contrasting functional readouts between cell lines, the study established clear biological distinctions separating high-risk variants from those conferring intermediate vulnerability.

Reflecting on the unexpected magnitude of the differences uncovered between cell types, Dace emphasized the novelty and broader implications of the comparative approach. She noted: “This was the first time anyone had compared the effects of thousands of variants edited into a gene between cell types. We didn’t expect to see so much difference between them. The work suggests that it’s important to investigate how variants in a particular gene function in the cell types most relevant to a particular disease, allowing researchers to generate datasets that could ultimately help make genetic risk assessment more precise.”

Findlay indicated that these findings could eventually transform clinical counseling by moving beyond simple binary categorizations of disease likelihood. He explained: “People can be told they have a mutation in BRCA1, but that its significance is unknown. This leaves them in the dark about their risk of developing cancer. Our work suggests that, ideally, people could be given a precise risk estimate, that not only gives the individual a clearer idea about their actual risk, but helps doctors make decisions about which monitoring or interventions would be most appropriate to offer.” By demonstrating that cellular context governs variant pathogenicity, the researchers anticipate that this strategy will substantially refine how genetic test results are interpreted in patient care.

Subject of Research: Cellular variation and cancer risk interpretation in BRCA1 genetic mutations

Article Title: Testing BRCA1 variants reveals differences in breast cancer risk

Article References: Testing BRCA1 variants reveals differences in breast cancer risk. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: BRCA1 gene, breast cancer risk, ovarian cancer, saturation genome editing, Francis Crick Institute, Nature Genetics, Genome Function Laboratory, Greg Findlay, Phoebe Dace, HAP1 cells, human mammary epithelial cells, DNA repair, cell growth, gene expression, variant pathogenicity, intermediate cancer risk, genetic risk assessment, cellular buffering